Nightingale Announces Joint Venture Agreement With ExpeData® To Launch Innovative EMR-Integrated Digital Pen Technology

Clinipen to enable physicians to enter information from paper directly into a patient's Electronic Medical Record

MARKHAM, ON, May 30, 2011 /CNW/ - Nightingale Informatix Corporation (TSX-V:NGH) ("Nightingale" or the "Company"), an application service provider (ASP) of Electronic Medical Record (EMR) software and related services today announced it has partnered with ExpeData, LLC ("ExpeData"), an innovative software company and global leader in digital writing, to launch "Clinipen", a potentially game-changing technology within the North American EMR market. Clinipen will enable EMR software providers to deliver an integrated digital writing solution with which healthcare providers can input structured data into a patient's EMR directly from paper.

"Through this partnership with Nightingale, we will be making the adoption of EMR technology much more appealing to a large segment of North American healthcare providers, which is very exciting," said Brandon Major, Vice President and COO, ExpeData. "We are looking forward to a successful launch of Clinipen."

The EDW® digital writing platform from ExpeData leverages Anoto® digital pen and paper technology and Vision Objects' industry-leading handwriting recognition technologies. ExpeData has demonstrated the effective use of its platform solution in a number of industries, including financial services and certain segments of the healthcare industry. Via the partnership, Nightingale and ExpeData will expand the deployment of the EDW® digital writing platform to the EMR market.

Nightingale and ExpeData have entered into a joint venture agreement for exclusive distribution rights for the Clinipen technology products for the EMR industry in North America. Each company will maintain 50% ownership.

Nightingale On Demand, Nightingale's leading, web-based EMR, will be the first solution seamlessly integrated with Clinipen. The Clinipen-enabled solution for Nightingale On Demand is expected to become commercially available to physicians in Canada and the United States during the fourth quarter of this calendar year.

"Nightingale is committed to innovation and making the transition from paper records to EMR as seamless as possible for physicians," said Sam Chebib, President and CEO of Nightingale. "Clinipen will be a major breakthrough in EMR data entry as it will allow healthcare providers to continue using their current paper forms to document patient encounters and write prescriptions. We believe integrating ExpeData's digital writing technology with Nightingale On Demand will position both companies as leaders in the North American EMR market."

In Canada, it is estimated that more than 60% of physicians are still using paper-based records.1 A recent independent survey conducted in the US indicated that only 34% of healthcare providers use a comprehensive EMR system, while 16% indicated using a partial system. 29% of respondents indicated that they are evaluating solutions, while 20% indicated that they have not yet started the adoption process. 2

ExpeData and Vision Objects are part of the digital writing investment portfolio held by Myrian Capital, a private equity firm focused on emerging technology businesses.

"Clinipen is a strategic opportunity and provides a natural way to expand our digital writing investment portfolio into the EMR market," said Paddy Padmanabhan, Managing Director, Myrian Capital. "The advanced input technologies in this joint venture allow physicians to use handwriting, the most natural and flexible data capture method available, to easily transition to electronic records. This provides groundbreaking potential to accelerate EMR adoption."

  1. 2009 Commonwealth Fund International Health Policy Survey of Primary Care Physicians
  2. 2nd Annual Healthcare IT Market: Insights and Opportunities Study, CompTIA, 2010

About Nightingale Informatix Corporation

Nightingale is one of the fastest growing healthcare service and software companies in North America. It is recognized as an industry leader in web based (ASP) clinician and community based electronic medical records (EMR) serving the needs of small primary care practices, multi-physician outpatient clinics, and large scale regional health organizations and networks. Coupled with integrated practice management, transcription and revenue cycle management, Nightingale's comprehensive service offering allows customers to enhance patient care, increase revenue opportunities and optimize operations. Nightingale is continuously innovating and enhancing its services to meet the needs of its growing and diverse customer base.  Nightingale - Healthcare connected.

About ExpeData, LLC

ExpeData® is an innovative software company and a global leader in digital writing. ExpeData has created the cost effective, end-to-end EDW® digital writing platform that automates the collection of handwritten information at the point of entry. Handwriting is captured in the field, immediately converted to digitized data and seamlessly integrated to backend business systems. This results in unsurpassed workflow optimization and significant cost reduction. Digital writing delivers significant benefits to organizations of all sizes. EDW solutions are used across the globe, delivering value in multiple industries. For more information, visit

Featuring Anoto Functionality The EDW® solutions are, in part, based on Anoto Digital Pen and Paper Technology, which is covered by over 200 patents worldwide, including but not limited to US6663008, US7172131, US7248250, US7281668, JP3872498, JP3842283, CN1595440, SE517445, RU2256225, and AU773011. "Anoto", "Magic Box" and the Anoto logotype are trademarks owned by Anoto AB.

Forward Looking Statement

This press release contains "forward-looking statements" respecting the issuance and cancellation of securities of the Company within the meaning of applicable Canadian securities legislation. Generally, forward-looking statements can be identified by the use of forward- looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may" ,"could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Nightingale to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the speculative nature of the medical software industry, which is affected by numerous factors beyond Nightingale's control; the ability of Nightingale to successfully integrate its acquisitions and any liabilities arising as a result of such acquisitions, access to capital and agreements with its Lenders; the existence of present and possible future government regulation; access to debt or equity financing and agreements with its Lenders; the significant and increasing competition that exists in the medical software industry; the early stage of Nightingale's business; and therefore it is subject to the risks associated with early stage companies, including uncertainty of revenues, markets and profitability and the need to raise additional funding.  All material assumptions used in making forward-looking statements are based on management's knowledge of current business conditions and expectations of future business conditions and trends. Although management believes the assumptions used to make such statements are reasonable at this time, our assumptions may not to be as anticipated, estimated or intended. Certain material factors or assumptions applied by management in making forward-looking statements, include without limitation, factors and assumptions regarding Nightingale's continued ability to fund its business, rates of customer defaults, relationships with, and payments to, lenders, demand for Nightingale's products, as well as Nightingale's operating cost structure.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


SOURCE Nightingale Informatix Corporation

For further information:


Media Inquiries
Michael McMillan
Veritas Communications
T 416.955.4583
Investor Inquiries
Kristen Dickson, M.Sc.
Equicom, a TMX Group Company
Tel: 416.815.0700 ext. 273

ExpeData, LLC
April D'Angelo
Director, Marketing and Corporate Communications


Profil de l'entreprise

Nightingale Informatix Corporation

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.